Patents Examined by Geetha P. Bansal
-
Soluble lymphotoxin-&bgr; receptors as therapeutic agents for the treatment of immunological disease
Patent number: 6403087Abstract: This invention relates to compositions and methods comprising “lymphotoxin-&bgr; receptor blocking agents”, which block lymphotoxin-&bgr; receptor signalling. Lymphotoxin-&bgr; receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-&bgr; receptor extracellular domain that act as lymphotoxin-&bgr; receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-&bgr; receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-&bgr; receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-&bgr; receptor signalling is provided.Type: GrantFiled: June 8, 1998Date of Patent: June 11, 2002Assignee: Biogen, Inc.Inventors: Jeffrey L. Browning, Christopher D. Benjamin, Paula S. Hochman -
Patent number: 6403560Abstract: An immunopotentiator containing peptide and hyaluronic acid extracted from chicken comb or mammalian skin or organ is provided, the immunopotentiator having a great immunopotentiation effect on biological organisms; additionally, a method for preparing the immunopotentiator is provided, comprising immersing and swelling chicken comb or mammalian skin or mammalian organ in a minced state and hydrolyzing the protein in the mincemeat to peptide.Type: GrantFiled: October 11, 2000Date of Patent: June 11, 2002Assignee: Adaptgen Pharmaceutical Co., Ltd.Inventor: Seiji Hayashi
-
Patent number: 6403095Abstract: The present invention relates to methods and compositions for eliciting an immune response and the prevention-and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. Optionally, the methods further comprise administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. “Antigenic molecule” as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex are in the range of 0.Type: GrantFiled: November 15, 1999Date of Patent: June 11, 2002Assignee: Fordham UniversityInventors: Pramod K. Srivastava, Rajiv Y. Chandawarkar
-
Patent number: 6403080Abstract: Disclosed are methods and compositions wherein opsonin-enhanced cells, that is, cells which have been 1) modified so as to express an opsonin from a recombinant nucleic acid, 2) modified so as to express higher levels of an endogenous opsonin, or 3) mixed with an exogenous opsonin, when administered to a subject, modulate the immune response in the recipient to a selected antigen or antigens contained in or attached to the cells.Type: GrantFiled: June 24, 1999Date of Patent: June 11, 2002Assignee: Whitehead Institute for Biomedical ResearchInventor: Andrew H. Segal
-
Patent number: 6399664Abstract: A method for treating malignant cells such as leukemia or chronic myeloid leukemia, in a mammal, comprising of administering to the mammal a leukemia therapeutically effective amount of reactive oxygen intermediates. A method of treating cancer in a mammal with cancer and modulating the mammal's immune system, comprising of administering to the mammal in need thereof a cancer therapeutically effective amount of reactive oxygen intermediates. A method of treating leukemia in a mammal with leukemia, comprising of administering to the mammal in need thereof a leukemia therapeutically effective amount of ozone into the mammal's blood and a leukemia therapeutically effective amount of ether lipids.Type: GrantFiled: December 3, 1997Date of Patent: June 4, 2002Inventor: Lisa Marlene Jefferys Smith
-
Patent number: 6399070Abstract: The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. Optionally, the methods further comprise administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. “Antigenic molecule” as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex are in the range of 0.Type: GrantFiled: November 15, 1999Date of Patent: June 4, 2002Assignee: Fordham UniversityInventors: Pramod K. Srivastava, Rajiv Y. Chandawarkar
-
Patent number: 6399069Abstract: The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. Optionally, the methods further comprise administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. “Antigenic molecule” as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex are in the range of 0.Type: GrantFiled: November 15, 1999Date of Patent: June 4, 2002Assignee: Fordham UniversityInventors: Pramod K. Srivastava, Rajiv Y. Chandawarkar
-
Patent number: 6399063Abstract: A method of inhibiting growth of tumor cells which overexpress a growth factor receptor or growth factor by treatment of the cells with antibodies which inhibit the growth factor receptor function, is disclosed. A method of treating tumor cells with antibodies which inhibit growth factor receptor function, and with cytotoxic factor(s) such as tumor necrosis factor, is also disclosed. By inhibiting growth factor receptor functions tumor cells are rendered more susceptible to cytotoxic factors.Type: GrantFiled: September 14, 1998Date of Patent: June 4, 2002Assignee: Genentech, Inc.Inventors: Robert M. Hudziak, H. Michael Shepard, Axel Ullrich, Brian M. Fendly
-
Patent number: 6395272Abstract: Multispecific multivalent molecules which are specific to an Fc receptor (FcR), and therapeutic uses and therapeutic uses and methods for making the molecules are described.Type: GrantFiled: June 22, 1998Date of Patent: May 28, 2002Assignee: Mederex, Inc.Inventors: Yashwant M. Deo, Joel Goldstein, Robert Graziano, Chezian Somasundaram
-
Patent number: 6391306Abstract: The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. Optionally, the methods further comprise administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. “Antigenic molecule” as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex are in the range of 0.Type: GrantFiled: November 15, 1999Date of Patent: May 21, 2002Assignee: Fordham UniversityInventors: Pramod K. Srivastava, Rajiv Y. Chandawarkar
-
Patent number: 6387374Abstract: The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. Optionally, the methods further comprise administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. “Antigenic molecule” as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex are in the range of 0.Type: GrantFiled: November 15, 1999Date of Patent: May 14, 2002Assignee: Fordham UniversityInventors: Pramod K. Srivastava, Rajiv Y. Chandawarkar
-
Patent number: 6387371Abstract: A method of inhibiting growth of tumor cells which overexpress a growth factor receptor or growth factor by treatment of the cells with antibodies which inhibit the growth factor receptor function, is disclosed. A method of treating tumor cells with antibodies which inhibit growth factor receptor function, and with cytotoxic factor(s) such as tumor necrosis factor, is also disclosed. By inhibiting growth factor receptor functions tumor cells are rendered more susceptible to cytotoxic factors.Type: GrantFiled: June 25, 1999Date of Patent: May 14, 2002Assignee: Genentech, Inc.Inventors: Robert M. Hudziak, H. Michael Shepard, Axel Ullrich, Brian M. Fendly
-
Patent number: 6383494Abstract: The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. Optionally, the methods further comprise administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. “Antigenic molecule” as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex are in the range of 0.Type: GrantFiled: November 15, 1999Date of Patent: May 7, 2002Assignee: Fordham UniversityInventors: Pramod K. Srivastava, Rajiv Y. Chandawarkar
-
Patent number: 6383491Abstract: The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. Optionally, the methods further comprise administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. “Antigenic molecule” as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment; the effective amounts of the complex are in the range of 0.Type: GrantFiled: November 15, 1999Date of Patent: May 7, 2002Assignee: Fordham UniversityInventors: Pramod K. Srivastava, Rajiv Y. Chandawarkar
-
Patent number: 6383492Abstract: The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. Optionally, the methods further comprise administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. “Antigenic molecule” as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex are in the range of 0.Type: GrantFiled: November 15, 1999Date of Patent: May 7, 2002Assignee: Fordham UniversityInventors: Pramod K. Srivastava, Rajiv Y. Chandawarkar
-
Patent number: 6383493Abstract: The present invention relates to methods and compositions for eliciting an immune response and the prevention-and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. Optionally, the methods further comprise administering antigen presenting cells sensitized with complexes-of hsps noncovalently bound to an antigenic molecule. “Antigenic molecule” as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex are in the range of 0.Type: GrantFiled: November 15, 1999Date of Patent: May 7, 2002Assignee: Fordham UniversityInventors: Pramod K. Srivastava, Rajiv Y. Chandawarkar
-
Patent number: 6379668Abstract: A method for the prevention or reversal of transplant rejection, or for therapy for autoimmune diseases, is provided comprising administering compounds such as monoclonal antibodies, that bind specifically to one or more preselected CD45R leukocyte antigens.Type: GrantFiled: June 17, 1999Date of Patent: April 30, 2002Assignees: Research Corporation Technologies, Inc., Alimmune, LLCInventors: Andrew I. Lazarovits, Sibrand Poppema
-
Patent number: 6379672Abstract: The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. Optionally, the methods further comprise administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. “Antigenic molecule” as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex are in the range of 0.Type: GrantFiled: November 15, 1999Date of Patent: April 30, 2002Assignee: Fordham UniversityInventors: Pramod K. Srivastava, Rajiv Y. Chandawarkar
-
Patent number: 6375953Abstract: The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. optionally, the methods further comprise administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. “Antigenic molecule” as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex are in the range of 0.Type: GrantFiled: November 15, 1999Date of Patent: April 23, 2002Assignee: Fordham UniversityInventors: Pramod K. Srivastava, Rajiv Y. Chandawarkar
-
Patent number: 6368593Abstract: This invention provides a method to enhance alloactivation in a mixed lymphocyte culture. Alloactivated cells are effective in treating tumors when implanted into a tumor site or coinjected with tumor cells as a vaccine. By enhancing alloactivation, more cell combinations achieve a threshold of activation adequate for use in therapy, and the level of cytokine secretion in proliferative phase cultures is generally increased.Type: GrantFiled: October 9, 1998Date of Patent: April 9, 2002Assignee: The Regents of the University of CaliforniaInventor: James A. Thompson